Загрузка...
Poly-ADP-ribose Polymerase Inhibitor Use in Ovarian Cancer: Expanding Indications and Novel Combination Strategies
The use of poly(ADP-ribose) polymerase inhibition (PARPi) is transforming the current standard of care for the treatment of ovarian cancer, with three different PARP inhibitors gaining U.S Food and Drug Administration (FDA) approval since 2014. Given the rapidly expanding use of PARP inhibitors, thi...
Сохранить в:
| Опубликовано в: : | Int J Gynecol Cancer |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8263126/ https://ncbi.nlm.nih.gov/pubmed/31118216 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ijgc-2019-000499 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|